Render Target: STATIC
Render Timestamp: 2024-11-22T11:16:06.808Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-11-19 23:03:09.368
Product last modified at: 2024-11-20T08:01:02.235Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CRBN (F4I7F) Rabbit mAb #60312

Filter:
  • WB
  • IP
  • IHC
  • IF

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 55
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Simple Western™ 1:50 - 1:250
    Immunoprecipitation 1:100
    Immunohistochemistry (Paraffin) 1:50 - 1:200
    Immunofluorescence (Frozen) 1:100 - 1:200
    Immunofluorescence (Immunocytochemistry) 1:100 - 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #95258.

    Protocol

    Specificity / Sensitivity

    CRBN (F4I7F) Rabbit mAb recognizes endogenous levels of total CRBN protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the central region of human CRBN protein.

    Background

    CRBN/Cereblon, a substrate receptor for the CRL4 E3 ubiquitin ligase, was originally identified for its role in autosomal recessive nonsyndromic mental retardation (1). CRBN’s role in the regulation of the AMPK pathway has been linked to various human diseases, including cardiovascular disease and obesity, and its involvement in proteasomal degradation may be important in neuropsychiatric diseases (2). CRBN has also been shown to enhance the effects of immunomodulatory drugs (IMiDs) in multiple myeloma, and may be a predictive marker for therapy (2-4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.